DE60309329T2 - Verbessertes transdermales abgabesystem - Google Patents

Verbessertes transdermales abgabesystem Download PDF

Info

Publication number
DE60309329T2
DE60309329T2 DE60309329T DE60309329T DE60309329T2 DE 60309329 T2 DE60309329 T2 DE 60309329T2 DE 60309329 T DE60309329 T DE 60309329T DE 60309329 T DE60309329 T DE 60309329T DE 60309329 T2 DE60309329 T2 DE 60309329T2
Authority
DE
Germany
Prior art keywords
tds
drug
matrix
amine
functional drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60309329T
Other languages
German (de)
English (en)
Other versions
DE60309329D1 (de
Inventor
Mike Woodstown HANNAY
Wilhelm Dietrich SCHACHT
Hans-Michael Wolff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Pharma GmbH
Original Assignee
Schwarz Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schwarz Pharma AG filed Critical Schwarz Pharma AG
Application granted granted Critical
Publication of DE60309329D1 publication Critical patent/DE60309329D1/de
Publication of DE60309329T2 publication Critical patent/DE60309329T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Feeding, Discharge, Calcimining, Fusing, And Gas-Generation Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60309329T 2002-07-30 2003-07-28 Verbessertes transdermales abgabesystem Expired - Lifetime DE60309329T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02016864 2002-07-30
EP02016864A EP1386604A1 (en) 2002-07-30 2002-07-30 Improved transdermal delivery system
PCT/EP2003/008319 WO2004012719A1 (en) 2002-07-30 2003-07-28 Improved transdermal delivery system

Publications (2)

Publication Number Publication Date
DE60309329D1 DE60309329D1 (de) 2006-12-07
DE60309329T2 true DE60309329T2 (de) 2008-04-17

Family

ID=30011092

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60309329T Expired - Lifetime DE60309329T2 (de) 2002-07-30 2003-07-28 Verbessertes transdermales abgabesystem

Country Status (21)

Country Link
EP (2) EP1386604A1 (cg-RX-API-DMAC7.html)
JP (1) JP4837915B2 (cg-RX-API-DMAC7.html)
KR (1) KR101016914B1 (cg-RX-API-DMAC7.html)
CN (1) CN100558350C (cg-RX-API-DMAC7.html)
AT (1) ATE343380T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003266252B2 (cg-RX-API-DMAC7.html)
BR (1) BR0313092A (cg-RX-API-DMAC7.html)
CA (1) CA2490573C (cg-RX-API-DMAC7.html)
CY (1) CY1105878T1 (cg-RX-API-DMAC7.html)
DE (1) DE60309329T2 (cg-RX-API-DMAC7.html)
DK (1) DK1524971T3 (cg-RX-API-DMAC7.html)
ES (1) ES2273042T3 (cg-RX-API-DMAC7.html)
IL (1) IL165917A (cg-RX-API-DMAC7.html)
MX (1) MXPA05000349A (cg-RX-API-DMAC7.html)
NO (1) NO334187B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ537476A (cg-RX-API-DMAC7.html)
PL (1) PL376999A1 (cg-RX-API-DMAC7.html)
PT (1) PT1524971E (cg-RX-API-DMAC7.html)
SI (1) SI1524971T1 (cg-RX-API-DMAC7.html)
WO (1) WO2004012719A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200500255B (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
EP1386605A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
ES2661767T3 (es) 2008-02-27 2018-04-03 Hisamitsu Pharmaceutical Co., Inc. Parche adhesivo para la piel y producto envasado
JP5537412B2 (ja) 2008-02-27 2014-07-02 久光製薬株式会社 貼付製剤
WO2011076879A1 (en) * 2009-12-22 2011-06-30 Ucb Pharma Gmbh Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
DE102011090178A1 (de) 2011-12-30 2013-07-04 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit geringer Neigung zur Spontankristallisation
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀(Rotigotine)之多天式貼片
CN105358139B (zh) 2013-07-03 2020-10-16 Lts罗曼治疗方法有限公司 具有电子元件的经皮治疗系统
ES2954087T3 (es) 2014-05-20 2023-11-20 Lts Lohmann Therapie Systeme Ag Sistema de administración transdérmica que incluye un mediador de interfase
CN106456567A (zh) 2014-05-20 2017-02-22 Lts勒曼治疗系统股份公司 在经皮递送系统中调节活性剂释放的方法
JP6573913B2 (ja) 2014-05-20 2019-09-11 エルテーエス ローマン テラピー−ジステーメ アーゲー ロチゴチンを含む経皮送達システム
DK3854388T3 (da) 2020-01-24 2023-11-27 Luye Pharma Switzerland Ag Transdermalt terapeutisk system omfattende rotigotin og mindst et ikke-aminresistent silikoneklæbestof
EP3949956A1 (en) * 2020-08-06 2022-02-09 LTS Lohmann Therapie-Systeme AG Esketamine-suspension-tts

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736577A (en) * 1995-01-31 1998-04-07 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
US5989586A (en) * 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
US5601839A (en) * 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE19814083C2 (de) * 1998-03-30 2002-02-07 Lohmann Therapie Syst Lts Verfahren zur Herstellung von transdermalen therapeutischen Systemen unter Verwendung von basischen Alkalimetallsalzen zur Umwandlung von Wirkstoffsalzen in die freien Basen
FR2792529B1 (fr) * 1999-04-26 2001-09-28 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques comprenant des derives de 2-isoxazole-8-aminotetralines
IT1311696B1 (it) * 1999-06-22 2002-03-19 Zanussi Elettromecc Compressore del fluido frigorigeno azionato da un motore elettricoa frequenza di alimentazione variabile
JP2002045699A (ja) * 2000-08-08 2002-02-12 Mitsubishi Electric Corp 排ガス浄化用層状電気化学触媒
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
DE10060550C1 (de) * 2000-12-06 2002-04-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten
CA2441064A1 (en) * 2001-03-16 2002-09-26 Andrx Corporation Controlled release sulfonylurea formulation
KR100904158B1 (ko) * 2001-03-16 2009-06-23 알자 코포레이션 펜타닐 투여용 경피성 패치
PT1256340E (pt) * 2001-05-08 2003-12-31 Sanol Arznei Schwarz Gmbh Sistema terapeutico transdermico aperfeicoado para o tratamento da doenca de parkinson
EP1386605A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine

Also Published As

Publication number Publication date
PT1524971E (pt) 2007-01-31
AU2003266252A1 (en) 2004-02-23
EP1524971A1 (en) 2005-04-27
NO334187B1 (no) 2014-01-13
IL165917A (en) 2007-07-24
HK1083458A1 (zh) 2006-07-07
PL376999A1 (pl) 2006-01-23
CA2490573A1 (en) 2004-02-12
NO20050770L (no) 2005-02-11
AU2003266252B2 (en) 2008-11-20
KR101016914B1 (ko) 2011-02-22
CA2490573C (en) 2011-06-07
WO2004012719A1 (en) 2004-02-12
EP1386604A1 (en) 2004-02-04
MXPA05000349A (es) 2005-03-31
IL165917A0 (en) 2006-01-15
ZA200500255B (en) 2006-01-25
ES2273042T3 (es) 2007-05-01
JP2005535686A (ja) 2005-11-24
NZ537476A (en) 2007-08-31
EP1524971B1 (en) 2006-10-25
JP4837915B2 (ja) 2011-12-14
CN100558350C (zh) 2009-11-11
SI1524971T1 (sl) 2007-02-28
ATE343380T1 (de) 2006-11-15
CY1105878T1 (el) 2011-02-02
CN1671365A (zh) 2005-09-21
DE60309329D1 (de) 2006-12-07
BR0313092A (pt) 2005-06-21
DK1524971T3 (da) 2007-02-19
KR20050025638A (ko) 2005-03-14

Similar Documents

Publication Publication Date Title
DE60304477T2 (de) Verbessertes transdermales abgabesystem für die verabreichung von rotigotin
EP1033978B1 (de) D2-agonist enthaltendes transdermales therapeutisches system zur behandlung des parkinson-syndroms und verfahren zu seiner herstellung
DE60021099T2 (de) Transdermale, in form einer haftschicht ausgebildete zweifachmedikamenten-verabreichungsvorrichtung
EP0186019B1 (de) Wirkstoffpflaster
DE60100994T2 (de) Transdermales therapeutisches System für die Erzielung hoher Plasmaspiegel von Rotigotin in der Therapie von Morbus Parkinson
DE3785015T2 (de) Elastische Vorrichtung zur transdermalen Wirkstofffreisetzung und Zusammensetzungen und Vorrichtungen, die Fettsäureester/-äther oder Alkandiole als Absortionssteigerer verwenden.
EP1178782B1 (de) Transdermales therapeutisches system (tts) tolterodin enthaltend
EP1103260B1 (de) Transdermalsystem zur Abgabe von Clonidin
DE69020875T2 (de) Oestrogenhaltiges Gelpräparat.
WO2004058247A1 (de) Vorrichtung zur transdermalen verabreichung von rotigotin-base
DE60311449T2 (de) Transdermales therapeutisches system mit zwei übereinanderliegenden matrixschichten, die verschiedene affinitäten zum enthaltenen wirkstoff ausweisen
EP1347749A2 (de) Transdermales therapeutisches system mit dem wirkstoff oxybutynin
EP0665745B1 (de) Pflaster zur transdermalen verabreichung von flüchtigen, pharmazeutisch wirksamen, chemisch basischen inhaltsstoffen und verfahren zu seiner herstellung
EP2797588B1 (de) Transdermales therapeutisches system mit geringer neigung zur spontankristallisation
EP0439180A2 (de) Transdermales therapeutisches System mit dem Wirkstoff Tulobuterol
DE3587698T2 (de) Pharmazeutische Präparate.
DE19812413C1 (de) Transdermales Therapeutisches System (TTS) Oxybutynin enthaltend
KR101016914B1 (ko) 향상된 경피 송달 시스템
EP0379933B1 (de) Superfizielles therapeutisches System mit einem Gehalt an einem antineoplastischen Wirkstoff, insbesondere 5-Fluoruracil
EP1530461B1 (de) Transdermale verabreichung von (r)-3,3-diphenylpropylamin-monoestern
EP2366388A1 (de) Nicht-okklusives transdermales therapeutisches System zur Verabreichung von Buprenorphin
DE102008006791B4 (de) Transdermales Therapeutisches System mit Harnstoff-Komponente und Verfahren zu dessen Herstellung
DE60108870T2 (de) Transdermales Verabreichungssystem für die Behandlung von Harnwegserkrankungen
EP4093383B1 (de) Transdermales therapeutisches system mit dem wirkstoff rotigotin und mindestens einem nicht aminresistenten silikonkleber
DE3843557A1 (de) Transdermales therapeutisches system zur verabreichung von clenbuterol

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: UCB PHARMA GMBH, 40789 MONHEIM, DE